Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC.Methods: A con...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-01-01
Serija:	Frontiers in Pharmacology
Teme:	hepatocellular carcinoma lenvatinib hepatitis B virus hepatitis C virus antiviral therapy
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1032881/full
Oznake:	Označite Brez oznak, prvi označite!